- Home
- RCUS vs NMRK Comparison
RCUS vs NMRK Comparison
Compare RCUS & NMRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | NMRK |
|---|---|---|
| Founded | 2015 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RCUS | NMRK |
|---|---|---|
| Price | $25.41 | $17.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $28.88 | $19.40 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | N/A | ★ 94.50 |
| EPS | N/A | ★ 0.59 |
| Revenue | $240,000,000.00 | ★ $3,160,782,000.00 |
| Revenue This Year | N/A | $21.82 |
| Revenue Next Year | N/A | $10.10 |
| P/E Ratio | ★ N/A | $29.04 |
| Revenue Growth | N/A | ★ 20.95 |
| 52 Week Low | $6.50 | $9.65 |
| 52 Week High | $26.40 | $19.84 |
Technical Indicators
Market Signals| Indicator | RCUS | NMRK |
|---|---|---|
| Relative Strength Index (RSI) | 71.57 | 49.45 |
| Support Level | $24.32 | $16.85 |
| Resistance Level | $26.40 | $17.97 |
| Average True Range (ATR) | 1.30 | 0.68 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 82.78 | 70.71 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.